人類及動物體骨組織不斷地進(jìn)行著重建，骨重建過程包括骨的分解吸收與新骨的形成。破骨細(xì)胞（Osteoclast，OC）負(fù)責(zé)骨分解與吸收，而成骨細(xì)胞（osteoblast，OB）負(fù)責(zé)新骨形成。破骨細(xì)胞貼附在舊骨區(qū)域，分泌酸性物質(zhì)溶解礦物質(zhì)，分泌蛋白酶消化骨基質(zhì)，形成骨吸收陷窩；其后，成骨細(xì)胞移行至被吸收部位，分泌骨基質(zhì)，骨基質(zhì)礦化而形成新骨。破骨與成骨過程的平衡是維持正常骨量的關(guān)鍵。   

       抗酒石酸酸性磷酸酶（TRAP，tartrate-resistant acid phosphatase）為破骨細(xì)胞的標(biāo)志酶，特異地分布于破骨細(xì)胞中，為破骨細(xì)胞所特有。通常作為鑒別破骨細(xì)胞的重要標(biāo)志物，使破骨細(xì)胞呈紅色。  

TRAP Staining Kit

       艾美捷科技作為專業(yè)的生命科學(xué)領(lǐng)域解決方案供應(yīng)商，為您推薦39年老品牌，Kamiya暢銷產(chǎn)品，眾多Nature文章使用認(rèn)證！

       * 產(chǎn)品僅限用于科研學(xué)術(shù)研究用途，不得用于醫(yī)療與診斷。  

       TRAP Staining Kit，Nature文章結(jié)果鑒賞：

       ①【Nature Medicine, IF=87.2】  

TRAP stain: TRAP染色 (osteoclasts (o/c))

        ② 【Nature Biomedical Engineering, IF=29.2】A multi-organ chip with matured tissue niches linked by vascular flow  

TRAP stain: TRAP染色

TRAP Activity: TRAP活性

       【更多發(fā)表文章】

      Sherlock, Jonathan P et al. "IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells". Nature medicinevol.18,7 (2012): 1069-76.

      Ronaldson-Bouchard, Kacey et al. "A multi-organ chip with matured tissue niches linked by vascular flow". Nature biomedical engineering vol.6,4 (2022): 351-371. doi:10.1038/s41551-022-00882-6

      Bae, Sung-Jin et al. "Ninjurin1 positively regulates osteoclast development by enhancing the survival of prefusion osteoclasts". Experimental & molecular medicine vol.51,1 (2019): 1-16.

      Kang, J., Choi, Y.J., Seo, B.Y. et al. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment. Sci Rep 9, 8726 (2019).

      Zhang, Lan, et al. "Adiponectin ameliorates experimental periodontitis in diet-induced obesity mice."PloS one 9.5 (2014): e97824.

      Kang, Moo Rim et al. "Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB". Marine drugs vol.12,11 (2014): 5643-56.

      Sherlock, Jonathan P., et al. "IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+ CD4? CD8? entheseal resident T cells."Nature medicine18.7 (2012): 1069-1076.

      Kim, Jinkoo, et al. "Erythropoietin mediated bone formation is regulated by mTOR signaling."Journal of cellular biochemistry113.(2012): 220-228.

      Lee, Yu-Chen, et al. "Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts."Oncogene 29.22 (2010): 3196-3207.

      Lu, Yi et al. "Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone". Clinical & experimental metastasis vol.26,2 (2009): 161-9. doi:10.1007/s10585-008-9226-7

      Geng, Weidong et al. "Inhibition of osteoclast formation and function by bicarbonate: role of soluble adenylyl cyclase". Journal of cellular physiology vol.220,2 (2009): 332-40.

      Simonaro, Calogera M., et al. "Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases."The American journal of pathology172.1(2008): 112-122.

       Kamiya Biomedical Company于1983年成立于美國加利福尼亞，1996年公司遷至華盛頓。Kamiya公司旨在為生命科學(xué)和醫(yī)學(xué)界提供高品質(zhì)的創(chuàng)新的實驗室研究和診斷工具。產(chǎn)品線包括數(shù)千種用于臨床前研究的人類和動物生物標(biāo)志物的檢測，是選擇非常多的ELISA試劑盒供應(yīng)商之一。Kamiya還提供各種其它生命科學(xué)研究產(chǎn)品，包括酶抑制劑和單克隆/多克隆抗體，用于多種領(lǐng)域，包括細(xì)胞凋亡、多藥耐藥性、氧化損傷/DNA損傷和修復(fù)、骨生物學(xué)、癌癥、心臟健康、炎癥、應(yīng)激、肥胖和糖尿病等。最近，Kamiya推出了新的創(chuàng)新K-ASSAY化學(xué)分析儀試劑，用于胰島素、D-二聚體、因子XIII、血漿FDP、血清/尿液FDP和總IgE檢測等。   

       看到這兒，您心動了嗎？馬上聯(lián)系Kamiya中國區(qū)總代理，艾美捷科技！